Table 1. Participant characteristics.
The table includes the sex, age, MMSE, and Aβ42 and T-Tau measures for 133 study participants. APOEε4 genotype was available for 131 participants. Sex ratio and age distribution was matched across groups to the best of our ability in order to mitigate the risk of associations between miRNA markers and diagnosis being confounded by these factors. Examination of each miRNA for association with each factor, both overall and within diagnostic groups, revealed no hints of confounding.
| NC | MCI | AD | All | ||
|---|---|---|---|---|---|
| Sex | Male | 27 (41.5%) | 19 (61.3%) | 23 (62.2%) | 69 (51.9%) |
|
|
|||||
| Female | 38 (58.5%) | 12 (38.7%) | 14 (37.8%) | 64 (48.1%) | |
|
|
|||||
| All | 65 | 31 | 37 | 133 | |
|
| |||||
| Age at LP † | Male | 27 (73.5±5.1) | 19 (75.2±5.8) | 23 (74.2±9.7) | 69 (74.2±7.0) |
|
|
|||||
| Female | 38 (72.7±4.8) | 12 (75.6±7.2) | 14 (67.7±9.8) | 64 (72.1±7.0) | |
|
|
|||||
| All | 65 (73.0±4.9) | 31 (75.4±6.3) | 37 (71.8±10.1) | 133 (73.2±7.1) | |
|
| |||||
| MMSE at LP † | Male | 27 (28.9±1.2) | 19 (26.8±1.5) | 22 (22.7±3.8) | 68 (26.3±3.6) |
|
|
|||||
| Female | 38 (29.2±1.3) | 11 (27.1±1.6) | 14 (19.7±5.1) | 63 (26.7±4.7) | |
|
|
|||||
| All | 65 (29.1±1.2) | 30 (26.9±1.5) | 36 (21.6±4.5) | 131 (26.5±4.1) | |
|
| |||||
| Aβ42 † | Male | 26 (724.8±332.6) | 18 (564.1±351.1) | 21 (337.8±202.4) | 65 (555.2±340.5) |
|
|
|||||
| Female | 33 (708.9±311.8) | 12 (431.0±209.6) | 8 (349.4±177.7) | 53 (591.7±311.6) | |
|
|
|||||
| All | 59 715.9±318.4) | 30 (510.8±305.5) | 29 341.0±192.8) | 118 (571.6±327.0) | |
|
| |||||
| T-Tau † | Male | 26 (291.2±134.2) | 18 (592.8±303.6) | 21 (580.2±278.9) | 65 (468.1±277.6) |
|
|
|||||
| Female | 33 (397.4±237.8) | 12 (538.0±215.5) | 8 (965.3±456.1) | 53 (515.0±335.7) | |
|
|
|||||
| All | 59 (350.6±204.4) | 30 (570.9±269.1) | 29 (686.5±371.8) | 118 (489.2±304.6) | |
|
| |||||
| Aβ42: T-Tau † | Male | 26 (2.8±1.3) | 18 (1.4±1.2) | 21 (0.9±1.4) | 65 (1.8±1.6) |
|
|
|||||
| Female | 33 (2.4±1.7) | 12 (1.0±0.8) | 8 (0.5±0.6) | 53 (1.8±1.6) | |
|
|
|||||
| All | 59 (2.6±1.5) | 30 (1.2±1.1) | 29 (0.8±1.3) | 118 (1.8±1.6) | |
|
| |||||
| Mean (Aβ42): Mean (T-Tau) ‡ | Male | 26 (2.5±0.3) | 18 (1.0±0.2) | 21 (0.6±0.1) | (65) 1.2 ± 0.1 |
|
|
|||||
| Female | 33 (1.8±0.2) | 12 (0.8±0.2) | 8 (0.4±0.1) | (53) 1.1 ± 0.2 | |
|
|
|||||
| All | 59 (2.0±0.2) | 30 (0.9±0.1) | 29 (0.5±0.1) | 118 (1.2±0.1) | |
|
| |||||
| APOEε4 Alleles (0-2) | 0 | 43 (66.2%) | 12 (40.0%) | 18 (50.0%) | 73 (55.7%) |
|
|
|||||
| 1 | 18 (27.7%) | 14 (46.7%) | 12 (33.3%) | 44 (33.6%) | |
|
|
|||||
| 2 | 4 (6.2%) | 4 (13.3%) | 6 (16.7%) | 14 (10.7%) | |
|
|
|||||
| All | 65 | 30 | 36 | 131 | |
†
reporting N (mean±SD)
‡
reporting N (mean±SE)